BioSpace News Archive

Elicio Therapeutics today announced the publication of preclinical data demonstrating its lymph node-targeting Amphiphile (AMP) adjuvant.

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today reported financial results for the three months ended June 30, 2023 and provided a corporate update.

Palisade Bio today reported that the Company’s U.S. Phase 2 PROFILE study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection did not achieve its primary endpoint.

Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG, “Company”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to provide an update on the company’s activities via the latest investor presentation attached.

Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2023.

CollPlant Biotechnologies today announced that it will report financial results for the second quarter of 2023 on Thursday, August 24, 2023, before the market open.

Daiichi Sankyo (TSE: 4568) today announced that VANFLYTA® (quizartinib) is now available by prescription in the U.S. VANFLYTA is the first and only FLT3 inhibitor to be approved by the U.S. Food and Drug Administration (FDA) specifically for FLT3-ITD positive acute myeloid leukemia (AML) and across the three phases of treatment – induction, consolidation and maintenance in patients without transplant – for newly diagnosed AML.

Agilent Technologies Inc. announced that Ajit Divakaruni, Ph.D., has received the Agilent 2023 Early Career Professor Award.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced second quarter and first half 2023 financial results and business updates.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ, a therapeutic in development for the treatment of Alzheimer’s Disease (“AD”), achieved positive preclinical end points in a study conducted at Washington University, St. Louis.